Refractory Neurogenic Detrusor Overactivity: How Far to Push Oral Therapy
A woman with lifelong spina bifida is still incontinent on a maximal antimuscarinic dose. The disagreement is whether to push oral therapy further with a second agent or stop iterating on pills altogether.
Yolanda P., a 41-year-old woman who runs an in-home daycare out of her converted garage and has raised two kids largely from a wheelchair, was born with a lumbar-level myelomeningocele and has performed clean intermittent catheterization since she was six years old — long enough that she describes it the way most people describe brushing their teeth, a fact of the day rather than a medical event. She has been on solifenacin 10mg, the top of its labeled range, for three years, after cycling through oxybutynin and tolterodine at standard doses without adequate control — fifteen years of continuous antimuscarinic therapy in all, begun at twenty-six, when the first urodynamic study of her adult care showed storage pressures her childhood catheterization schedule was no longer holding down on its own. She still leaks between catheterizations most afternoons, badly enough on the daycare's chaotic pickup days that she has started scheduling an extra midday catheterization specifically to get ahead of it, an accommodation none of the kids' parents know she's making.
Her bladder diary over the past month shows breakthrough incontinence on eighteen of twenty-eight days despite the maximal solifenacin dose, and her post-void residual on catheterization has crept up to 90mL from a baseline near 40mL a year ago — a real change, not measurement noise, and one that argues her detrusor overactivity itself may be worsening rather than her current dose simply having been undersized from the start. Amend et al.'s trial of combined high-dose antimuscarinic therapy in neurogenic detrusor dysfunction found real added benefit from doubling beyond label dose or combining two agents, without a corresponding rise in reported side effects in that small cohort — evidence that exists, but was never built to tell a clinician whether a patient already at fifteen years of continuous antimuscarinic exposure, not the trial's typical shorter horizon, should be the one absorbing an escalation with even thinner long-term safety data behind it than the drug she's already on. Combining two agents also means combining two different receptor-subtype profiles rather than simply doubling one dose, a distinction the trial's own design collapsed into a single 'combination' arm without separating which pairing drove the benefit it found.
Follow-up visit, eleven years into adult care
Add a second antimuscarinic rather than push solifenacin past its own labeled ceiling. I'll grant the trial doesn't isolate the version I'm proposing — Amend's cohort got there by doubling doses as well as by combining agents, so its benefit can't be attributed cleanly to the combining alone. But two agents each inside its own approved range is the more conservative half of what that study tested, and it found real added benefit without a rise in reported side effects. Her rising post-void residual argues her overactivity is getting worse, not that her current drug was always undersized, which is exactly the population that trial's design fits.
That trial's own cohort wasn't followed anywhere near as long as Yolanda has already been on antimuscarinic therapy — she's fifteen years into continuous exposure, most of it before we have any long-term combination safety data at all.
Dr. Alvarez's point about her rising residual is fair evidence her disease is progressing, but progression is exactly the argument for stopping oral escalation, not continuing it — a bladder that's already showing early signs of impaired emptying is one where adding more anticholinergic load raises real retention risk on top of whatever benefit it buys.
I'd frame this around what she's actually asking for, which isn't a stronger pill — it's not having to schedule around her own bladder at work. OnabotulinumtoxinA is proven in exactly her population, and she's already catheterizing on a fixed schedule; a modest rise in retention risk from injection doesn't change her day-to-day life the way it would for someone not already doing CIC.
I don't think either oral option on the table gets her durably past where she is now, and fifteen years of antimuscarinic exposure without escalation is itself a reasonable stopping point to bring to her directly, not just decide among ourselves.
Agreed: proceed to onabotulinumtoxinA injection, continue solifenacin at current dose until the injection takes full effect, then reassess for taper.
Not agreed: the urologist would have tried combination antimuscarinic therapy first per Amend's trial before moving to injection, and views this as skipping a real, evidence-supported step rather than a wrong choice — conceded as reasonable in isolation, but outweighed here by Yolanda's own fifteen years of exposure and her stated preference, once presented with both paths, for the option less likely to need revisiting in another two years.